Variation in Cardiac Screening and Management of Carcinoid Heart Disease in the UK and Republic of Ireland

摘要: Abstract Aims Screening for carcinoid heart disease is an important, yet frequently neglected aspect of the management patients with neuroendocrine tumours (NETs). advocated in international guidelines, although recommendations on modality and frequency are poorly defined. We mapped current practice screening specialist NET centres throughout UK Republic Ireland. Materials methods Thirty-five were invited to complete online questionnaire outlining size service, patient selection criteria screening. Results Twenty-eight responded (80%), representing over 5500 patients. Eleven per cent screen all any NET, 14% only midgut NETs, 32% liver metastases and/or syndrome 43% evidence or raised urinary/serum/plasma 5-hydroxyindoleacetic acid (5HIAA). The mode included clinical examination, echocardiography biomarker measurement: 89% carry out echocardiography, ranging from at initial presentation (24%), periodically without clearly defined intervals (28%), annually (36%) less than (12%); three use a scoring system report their echocardiograms. Fifty utilise biomarkers (chromogranins, plasma/urinary 5HIAA most commonly N-terminal pro-brain natriuretic peptide) varying time intervals. Conclusion There considerable heterogeneity across Ireland multiple aspects disease.